GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis
W. L. Gore & Associates, Inc. · Decision date Jan 15, 2026
What did the FDA approve?
FDA records P230023/S010 as a supplement to PMA P230023, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Jan 15, 2026.
FDA approval order statement
approval of the revised protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P230023.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Cardiovascular
- Decision date
- Jan 15, 2026
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P230023/S010
- Regulatory pathway
- PMA supplement
- Applicant
- W. L. Gore & Associates, Inc.
- Product code
- QZK
- Decision code
- APPR
- Decision date
- Jan 15, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Endovascular system for treatment of thoracoabdominal and pararenal aortic lesions.
- Applicant
- W. L. Gore & Associates, Inc.
- Product code
- QZK
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P230023/S010 received
Application receipt date recorded by FDA.
P230023/S009 · Related supplement
GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis
P230023/S010 · FDA decision
Normal 180 Day Track No User Fee
P230023/S011 · Related supplement
GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis (TAMBE)
P230023/S012 · Related supplement
GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis
Timeline entries are records held by MedtechLedger for P230023. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230023
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| W. L. Gore & Associates, Inc. | PMA supplement | Sep 9, 2025 | FDA | |
| W. L. Gore & Associates, Inc. | PMA supplement | Apr 9, 2026 | FDA | |
| W. L. Gore & Associates, Inc. | PMA supplement | Jul 1, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
W. L. Gore & Associates, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3450 W. Kiltie Ln., Flagstaff, AZ, 86005
Sources and methodology
- Original FDA record: P230023/S010
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
